Core Viewpoint - WuXi AppTec (药明康德) has reported its best-ever half-year performance for 2025, with significant revenue and profit growth driven by investment gains and reduced expenses [2][3][4]. Financial Performance - For the first half of 2025, WuXi AppTec achieved revenue of 20.799 billion yuan, a year-on-year increase of 20.64% [4][5]. - The net profit attributable to shareholders reached 8.561 billion yuan, marking a year-on-year growth of 101.92%, the first time the company has doubled its net profit in the first half since its A-share listing [4][9]. - Investment income for the first half of 2025 was 3.669 billion yuan, significantly up from 22 million yuan in the same period last year, primarily due to the sale of shares in an associate company [9]. Cost Management - WuXi AppTec has successfully reduced management and R&D expenses in the first half of 2025, with management expenses at 1.175 billion yuan and R&D expenses at 514 million yuan, both showing a decrease compared to the previous year [3][10]. - Sales expenses were 394 million yuan, accounting for 1.89% of revenue, down from 2.08% in the previous year [10]. Business Segments - The chemical business generated 16.3 billion yuan in revenue, a 33.5% increase year-on-year, while the small molecule drug discovery business contributed 8.68 billion yuan, up 17.5% [6]. - The TIDES business saw remarkable growth, with revenue reaching 5.03 billion yuan, a 141.6% increase [6]. - The testing business generated 2.69 billion yuan, with laboratory analysis and testing contributing 1.89 billion yuan, a slight increase of 0.4% [6]. Regional Performance - Revenue from U.S. clients was 14.03 billion yuan, up 38.4%, while European clients contributed 2.33 billion yuan, a 9.2% increase. Revenue from Chinese clients decreased by 5.2% to 3.15 billion yuan [7]. Future Outlook - WuXi AppTec has raised its full-year revenue guidance for 2025, expecting a growth rate of 13% to 17%, up from the previous estimate of 10% to 15% [7]. - The company reported a backlog of 56.69 billion yuan in ongoing business, a 37.2% increase year-on-year, indicating strong future demand [8]. Market Reaction - Following the impressive half-year results, WuXi AppTec's A-shares rose by 7.72% and H-shares increased by 11.25% on July 28 [12].

Core Viewpoint - WuXi AppTec, a leading CRO company, reported strong financial performance for the first half of 2025, with significant revenue and profit growth, and announced its first interim dividend to share growth benefits with global investors [1][2][3]. Financial Performance - The company achieved a revenue of 20.799 billion yuan in the first half of 2025, representing a year-on-year increase of 20.64% [1][2]. - Net profit attributable to shareholders reached 8.56 billion yuan, marking a substantial year-on-year growth of 101.92% [1][2]. - Adjusted Non-IFRS net profit was 6.31 billion yuan, up 44.4% year-on-year, with a net profit margin reaching a historical high of 30.4% [2][3]. - Operating cash flow was 7.07 billion yuan, a significant increase of 49.1% year-on-year, providing ample resources for capacity expansion and shareholder returns [2][3]. Orders and Growth Drivers - The company reported a record high of 56.69 billion yuan in backlog orders, reflecting a year-on-year growth of 37.2% [2][3]. - The small molecule CDMO pipeline exceeded 3,400 projects, with 412 new additions in the first half of 2025 [2]. - Revenue from TIDES (oligonucleotides and peptides) reached 5.03 billion yuan, showing a remarkable year-on-year growth of 141.6%, becoming a new growth engine for the company [2]. Shareholder Returns - The board approved the first-ever interim dividend of 3.5 yuan per 10 shares, totaling approximately 1 billion yuan [3]. - Cumulative shareholder returns since the beginning of 2025 are approaching 7 billion yuan, including completed dividends and share buybacks [3]. - The company plans to increase buyback efforts if the stock price remains undervalued, with total shareholder returns expected to reach 8 billion yuan for the year [3]. Revised Guidance - The company raised its full-year guidance for 2025, increasing the revenue growth forecast from 10%-15% to 13%-17%, with total revenue expectations adjusted from 41.5 billion-43 billion yuan to 42.5 billion-43.5 billion yuan [3]. - Free cash flow projections were revised upward from 4 billion-5 billion yuan to 5 billion-6 billion yuan [3]. - Capital expenditures are maintained at 7 billion-8 billion yuan for global capacity and capability building [3]. Institutional Holdings - As of July 28, 2025, 395 institutional investors held shares in WuXi AppTec, with a total holding of 1.159 billion shares, accounting for 40.37% of total shares [4]. - The top ten institutional investors collectively held 32.40% of shares, with an increase of 2.81 percentage points from the previous quarter [4]. - There were 53 public funds that increased their holdings, while 154 public funds reduced their holdings compared to the previous quarter [5].

出品 | 妙投APP 实际上，2022年FDA就通过了《FDA现代化法案2.0》，提倡寻找动物实验的替代方案，但最新政策更加具体，指明了智能计算模 型、类器官与器官芯片、跨物种数据整合的三大替代方向。这是该消息一经发布，市场关注度较高的重要原因。 受此消息影响，昭衍新药资本市场当天直接跌停。 不过市场对此争议较大，有人认为，"不用动物直接在人身上做试验，这不是开玩笑吗？"，也有人认为，这是猴子我国多，特意出 政策限制的；但也有人认为，或许不是空穴来风，真有可能实现，因为给了更具体的替代思路。如若真是这样，昭衍新药的猴子或 许就白囤了。 接下来从动物实验替代方案的可行性以及结合昭衍新药的中美业务占比等角度，关于该政策对昭衍新药的业务短中长期影响进行分 析。 动物实验并未被取缔，但未来可能会减少 其实有关取消动物实验的话题，这两年一直在业界讨论。 数十年来，动物一直是新药研究的关键。因为许多动物在生物学上与人类足够相似，而且会患上与人类相同的疾病，所以动物试验 能较大程度规避在人身上可能出现的危险。 作者 | 张贝贝 头图 | AI生图 4月11日消息，FDA官网更新政策，逐步取消单克隆抗体疗法等药物研发中对动物 ...

股票简称：万邦医药 股票代码：301520 安徽万邦医药科技股份有限公司 Anhui Wanbang Pharmaceutical Technology Co.,Ltd. （安徽省合肥市高新区明珠大道与火龙地路交口西南角安徽万邦医药 1 号楼） 二零二三年九月 特别提示 安徽万邦医药科技股份有限公司（以下简称"万邦医药"、"本公司"或"发 行人"、"公司"）股票将于 2023 年 9 月 25 日在深圳证券交易所创业板上市， 该市场具有较高的投资风险。创业板公司具有业绩不稳定、经营风险高、退市风 险大等特点，投资者面临较大的市场风险。投资者应充分了解创业板市场的投资 风险及本公司所披露的风险因素，审慎做出投资决定。 本公司提醒投资者应充分了解股票市场风险以及本公司披露的风险因素，在 新股上市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 如无特别说明，本上市公告书中的简称或名词的释义与本公司首次公开发行 股票并在创业板上市招股说明书中的相同。 首次公开发行股票并在创业板上市 之 上市公告书 保荐人（主承销商） （中国（上海）自由贸易试验区浦明路 8 号） 1 | | | | 特别提示 | 1 | | -- ...